Method of inhibiting dyrk1b
Assignee4SC Discovery GmbH
InventorsFritz ABERGER, Wolfgang GRUBER, Johann LEBAN, Hella KOHLHOF, Daniel VITT, Roland BAUMGARTNER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
Claims12
A method for in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, comprising administering to a subject in need thereof an effective amount of a DYRK1B inhibitor.
A method of inhibiting DYRK1B in vitro, said method comprising adding a DYRK1B inhibitor to a sample comprising cancer cells wherein the hedgehog signaling pathway is activated.
A therapy for preventing the formation of resistance of cancer cells against chemotherapeutic agents in a patient suffering from cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, comprising administering to said patient an effective amount of a DYRK1B inhibitor.
Dependencies are inferred from the claim text.